Posts tagged ALK-postive
PCN129 PREVENTING BRAIN METASTASES WITH ALECTINIB IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER: ECONOMIC IMPACT UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

Objectives: Results of the ALEX trial demonstrated that alectinib decreased the risk of Central Nervous System (CNS) progression and prolonged progression-free survival of NSCLC ALK+ patients, compared with crizotinib. The objective of this study is to compare the economic burden of CNS progression with alectinib versus crizotinib, on the Brazilian private healthcare system. Conclusions: Alectinib can potentially decrease the economic burden of CNS metastasis of NSCLC ALK+ patients in the Brazilian private healthcare system, compared with the current standard of care. READ ARTICLE

Value in Health DOI:10.1016/j.jval.2019.04.253

Authors: D.Kashiura, M.Santos, L.Carmo, R.Leme-Souza

Read More